SCHEMBL19638022

SCHEMBL19638022

COC(=O)c1ccc(C(=O)Nc2nc(-c3ccccc3)c(F)s2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.50
RAB9A P51151 5/20 0.50
MEN1 O00255 5/20 0.50
NPSR1 Q6W5P4 4/20 0.50
LMNA P02545 3/20 0.50
PKM P14618 1/20 0.50
ALOX5 P09917 1/20 0.49
ALDH1A1 P00352 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
NPC1 O15118 4/20 0.48
RXFP1 Q9HBX9 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ADORA1 P30542 3/20 0.47
ADORA3 P0DMS8 4/20 0.47
MAPT P10636 3/20 0.46
HSD17B10 Q99714 2/20 0.46
HTT P42858 1/20 0.46
MAPK1 P28482 1/20 0.46
HPGD P15428 2/20 0.44
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19638277 0.90 SMN1; SMN2 (0.52) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19638078 0.86 KMT2A (0.50) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL21168721 0.86 KMT2A (0.50) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19637967 0.86 KMT2A (0.50) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19638040 0.83 ADORA2A (0.60) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19638006 0.81 KMT2A (0.54) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19638110 0.75 RAB9A (0.51) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19650271 0.75 KMT2A (0.51) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19638183 0.75 KMT2A (0.51) KMT2ARAB9AMEN1NPSR1LMNA
SCHEMBL19638017 0.74 MAPT (0.52) KMT2ARAB9AMEN1NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207445-B Adenosine A3Modulators of receptors 帕罗生物制药有限公司 2021-03-16 CN disclosed
EP-3248964-B1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA SL (ES) 2019-07-17 EP disclosed
US-10238637-B2 Modulators of the adenosine A3 receptors PALOBIOFARMA, S.L. (ES) 2019-03-26 US disclosed
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS PALOBIOFARMA, S.L. (ES) 2018-09-20 US disclosed
EP-3248964-A1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA S.L. (ES) 2017-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS ADORA3, ADORA2A, ADORA1 KMT2A 4093/4885RAB9A 2858/4885MEN1 3374/4885
US-10238637-B2 Modulators of the adenosine A3 receptors ADORA3, ADORA2A, ADORA1 KMT2A 4093/4885RAB9A 2858/4885MEN1 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.